AMAG Pharmaceuticals on roadshow for $450 million eight-year notes

By Paul A. Harris

Portland, Ore., Aug. 5 – AMAG Pharmaceuticals Inc. began a roadshow on Wednesday for a $450 million offering of eight-year senior notes (B+), according to an informed source.

The roadshow wraps up on Aug. 12.

Jefferies LLC is the left bookrunner for the Rule 144A and Regulation S for life offering. Barclays is the joint bookrunner.

The notes become callable after three years at par plus 75% of the coupon

The Waltham, Mass.-based specialty pharmaceutical company plans to use the proceeds to help fund the acquisition of Cord Blood Registry, a stem cell collection and storage company serving pregnant women and their families, from GTCR for $700 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.